{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T11:56:18Z","timestamp":1792410978334,"version":"4.4.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.therap.2025.07.002","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T15:08:40Z","timestamp":1753456120000},"page":"200-211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Drugs associated with behavioral addictions: Real world analysis using the WHO pharmacovigilance database"],"prefix":"10.1016","volume":"81","author":[{"given":"Louis","family":"Asselin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edouard-Jules","family":"Laforgue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Duval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Revol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwena\u00eblle","family":"Veyrac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Grall-Bronnec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Victorri-Vigneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2025.07.002_bib0245","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1111\/j.1360-0443.1990.tb01620.x","article-title":"Addiction: definition and implications","volume":"85","author":"Goodman","year":"1990","journal-title":"Br J Addict"},{"key":"10.1016\/j.therap.2025.07.002_bib0250","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.bcp.2007.07.030","article-title":"Neurobiology of addiction. An integrative review","volume":"75","author":"Goodman","year":"2008","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.therap.2025.07.002_bib0255","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/add.16081","article-title":"The opioid epidemic: a worldwide exploratory study using the WHO pharmacovigilance database","volume":"118","author":"Robert","year":"2023","journal-title":"Addiction"},{"key":"10.1016\/j.therap.2025.07.002_bib0260","unstructured":"World Health Organization. ICD-11. 2025. https:\/\/icd.who.int\/en [Accessed 22 July 2025]."},{"key":"10.1016\/j.therap.2025.07.002_bib0265","series-title":"DSM-5\u00a0: manuel diagnostique et statistique des troubles mentaux","author":"Crocq","year":"2015"},{"key":"10.1016\/j.therap.2025.07.002_bib0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.addbeh.2013.09.004","article-title":"Non-substance addictive behaviors in the context of DSM-5","volume":"39","author":"Potenza","year":"2014","journal-title":"Addict Behav"},{"key":"10.1016\/j.therap.2025.07.002_bib0275","first-page":"100510","article-title":"Should problematic sexual behavior be viewed under the scope of addiction? A systematic review based on DSM-5 substance use disorder criteria","volume":"18","author":"Pistre","year":"2023","journal-title":"Addict Behav Rep"},{"key":"10.1016\/j.therap.2025.07.002_bib0280","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.neubiorev.2014.10.013","article-title":"The use of repetitive transcranial magnetic stimulation for modulating craving and addictive behaviours: a critical literature review of efficacy, technical and methodological considerations","volume":"47","author":"Grall-Bronnec","year":"2014","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.therap.2025.07.002_bib0285","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/1520-6394(2000)11:4<185::AID-DA8>3.0.CO;2-H","article-title":"Pathological gambling behaviour: emergence secondary to treatment of Parkinson's disease with dopaminergic agents","volume":"11","author":"Seedat","year":"2000","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.therap.2025.07.002_bib0290","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/1531-8257(200009)15:5<869::AID-MDS1016>3.0.CO;2-I","article-title":"Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment?","volume":"15","author":"Molina","year":"2000","journal-title":"Mov Disord"},{"key":"10.1016\/j.therap.2025.07.002_bib0295","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00429-011-0314-0","article-title":"Impulse control disorders in Parkinson's disease: seeking a roadmap toward a better understanding","volume":"216","author":"Cilia","year":"2011","journal-title":"Brain Struct Funct"},{"key":"10.1016\/j.therap.2025.07.002_bib0300","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s40290-022-00453-9","article-title":"Drug-induced gambling disorder: epidemiology, neurobiology, and management","volume":"37","author":"Wolfschlag","year":"2023","journal-title":"Pharm Med"},{"key":"10.1016\/j.therap.2025.07.002_bib0305","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40264-017-0590-6","article-title":"Dopamine agonists and impulse control disorders: a complex association","volume":"41","author":"Grall-Bronnec","year":"2018","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2025.07.002_bib0310","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/JCP.0000000000000444","article-title":"Pathological gambling associated with aripiprazole or dopamine replacement therapy: do patients share the same features? A review","volume":"36","author":"Grall-Bronnec","year":"2016","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.therap.2025.07.002_bib0315","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.addbeh.2013.11.005","article-title":"Aripiprazole: a new risk factor for pathological gambling? A report of 8 case reports","volume":"39","author":"Gaboriau","year":"2014","journal-title":"Addict Behav"},{"key":"10.1016\/j.therap.2025.07.002_bib0320","unstructured":"Aripiprazole. R\u00e9sum\u00e9 des caract\u00e9ristiques du produit. 2024. http:\/\/base-donnees-publique.medicaments.gouv.fr\/affichageDoc.php?specid=64807679&typedoc=R [Accessed 22 July 2025]."},{"key":"10.1016\/j.therap.2025.07.002_bib0325","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/pcn.13511","article-title":"Exploring the underlying mechanisms of drug-induced impulse control disorders: a pharmacovigilance-pharmacodynamic study","volume":"77","author":"Fusaroli","year":"2023","journal-title":"Psychiatry Clin Neurosci"},{"key":"10.1016\/j.therap.2025.07.002_bib0330","unstructured":"Uppsala Monitoring Center. About VigiBase. 2025. https:\/\/who-umc.org\/vigibase\/ [Accessed 22 July 2025]."},{"key":"10.1016\/j.therap.2025.07.002_bib0335","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40264-013-0131-x","article-title":"vigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues","volume":"37","author":"Bergvall","year":"2014","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2025.07.002_bib0340","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.therap.2025.07.002_bib0345","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.3390\/nu12123883","article-title":"Exploring patterns of disturbed eating in psychosis: a scoping review","volume":"12","author":"Stogios","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.therap.2025.07.002_bib0350","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1097\/jcp.0b013e31815a8872","article-title":"Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study","volume":"27","author":"Kluge","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.therap.2025.07.002_bib0355","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s00702-007-0663-2","article-title":"Clozapine\/olanzapine-induced recurrence or deterioration of binge eating-related eating disorders","volume":"114","author":"Gebhardt","year":"2007","journal-title":"J Neural Transm (Vienna)"},{"key":"10.1016\/j.therap.2025.07.002_bib0360","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00702-002-0792-6","article-title":"Spectrum of binge eating symptomatology in patients treated with clozapine and olanzapine","volume":"110","author":"Theisen","year":"2003","journal-title":"J Neural Transm (Vienna)"},{"key":"10.1016\/j.therap.2025.07.002_bib0365","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1089\/jpm.2018.0364","article-title":"Resurgence of eating disorders with olanzapine","volume":"22","author":"Wu","year":"2019","journal-title":"J Palliat Med"},{"key":"10.1016\/j.therap.2025.07.002_bib0370","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3389\/fpsyt.2020.00318","article-title":"Recurrent episodes of paraphilic behavior possibly associated with olanzapine and aripiprazole treatment in a patient with schizophrenia","volume":"11","author":"Stefanou","year":"2020","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.therap.2025.07.002_bib0375","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1176\/ajp.149.10.1408","article-title":"Possible clozapine exacerbation of bulimia nervosa","volume":"149","author":"Brewerton","year":"1992","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.therap.2025.07.002_bib0380","first-page":"48","article-title":"Compulsive buying and pathological gambling behavior associated with the use of selective serotonin reuptake inhibitors","volume":"33","author":"Ladhari","year":"2019","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2025.07.002_bib0385","doi-asserted-by":"crossref","first-page":"115415","DOI":"10.1016\/j.psychres.2023.115415","article-title":"Iatrogenic triggers for anorexia nervosa and bulimia nervosa: a WHO safety database disproportionality analysis","volume":"327","author":"Merino","year":"2023","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.therap.2025.07.002_bib0390","unstructured":"Haute Autorit\u00e9 de sant\u00e9. Guide d\u2019analyse de la litt\u00e9rature et gradation des recommandations. 2006. https:\/\/www.has-sante.fr\/jcms\/c_434715\/fr\/guide-d-analyse-de-la-litterature-et-gradation-des-recommandations [Accessed 22 July 2025]."},{"key":"10.1016\/j.therap.2025.07.002_bib0395","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/BF03262002","article-title":"Global patterns of adverse drug reactions over a decade","volume":"35","author":"Aagaard","year":"2012","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2025.07.002_bib0400","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s40264-019-00861-y","article-title":"Data-driven identification of adverse event reporting patterns for Japan in VigiBase, the WHO global database of individual case safety reports","volume":"42","author":"Wakao","year":"2019","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2025.07.002_bib0405","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.therap.2017.08.006","article-title":"Les \u00e9tudes cas\u2013non cas: principe, m\u00e9thodes, biais et interpr\u00e9tations","volume":"73","author":"Faillie","year":"2018","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2025.07.002_bib0410","first-page":"791573","article-title":"Eating disorders in schizophrenia: implications for research and management","volume":"2014","author":"Kouidrat","year":"2014","journal-title":"Schizophr Res Treat"},{"key":"10.1016\/j.therap.2025.07.002_bib0415","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/JCP.0000000000001357","article-title":"Binge eating disorders in antipsychotic-treated patients with schizophrenia: prevalence, antipsychotic specificities, and changes over time","volume":"41","author":"de Beaurepaire","year":"2021","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.therap.2025.07.002_bib0420","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13041-020-00621-5","article-title":"Clozapine generates obsessive compulsive disorder-like behavior in mice","volume":"13","author":"Kang","year":"2020","journal-title":"Mol Brain"},{"key":"10.1016\/j.therap.2025.07.002_bib0425","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/acps.13567","article-title":"Antipsychotics and obsessive-compulsive disorder\/obsessive-compulsive symptoms: a pharmacovigilance study of the FDA adverse event reporting system","volume":"148","author":"Burk","year":"2023","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.therap.2025.07.002_bib0430","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1055\/s-0029-1216356","article-title":"Dynamics of neuronal circuits in addiction: reward, antireward, and emotional memory","volume":"42","author":"Koob","year":"2009","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.therap.2025.07.002_bib0435","doi-asserted-by":"crossref","first-page":"a039628","DOI":"10.1101\/cshperspect.a039628","article-title":"Neural substrates and circuits of drug addiction","volume":"11","author":"Feltenstein","year":"2021","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.therap.2025.07.002_bib0440","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/nyas.13989","article-title":"The neurobiology of addiction","volume":"1451","author":"Uhl","year":"2019","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.therap.2025.07.002_bib0445","first-page":"359","article-title":"Neurobiology of food addiction","volume":"13","author":"Blumenthal","year":"2010","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"10.1016\/j.therap.2025.07.002_bib0450","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2165\/00023210-200822020-00004","article-title":"Pathological gambling: an update on neuropathophysiology and pharmacotherapy","volume":"22","author":"Iancu","year":"2008","journal-title":"CNS Drugs"},{"key":"10.1016\/j.therap.2025.07.002_bib0455","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1177\/070674371305800503","article-title":"A targeted review of the neurobiology and genetics of behavioral addictions: an emerging area of research","volume":"58","author":"Leeman","year":"2013","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.therap.2025.07.002_bib0460","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/bs.irn.2016.04.002","article-title":"Neurobiological basis of hypersexuality","volume":"129","author":"K\u00fchn","year":"2016","journal-title":"Int Rev Neurobiol"},{"key":"10.1016\/j.therap.2025.07.002_bib0465","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/070674370204700106","article-title":"Atypical antipsychotics: mechanism of action","volume":"47","author":"Seeman","year":"2002","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.therap.2025.07.002_bib0470","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s10899-013-9360-2","article-title":"Citalopram-associated gambling: a case report","volume":"30","author":"Cuomo","year":"2014","journal-title":"J Gambl Stud"},{"key":"10.1016\/j.therap.2025.07.002_bib0475","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1365-2125.2007.02861.x","article-title":"Evidence of zolpidem abuse and dependence: results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey","volume":"64","author":"Victorri-Vigneau","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2025.07.002_bib0480","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1056\/NEJM200402263500922","article-title":"Transient improvement of aphasia with zolpidem","volume":"350","author":"Cohen","year":"2004","journal-title":"N Engl J Med"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595725001040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595725001040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T13:36:29Z","timestamp":1779370589000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595725001040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0040595725001040"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2025.07.002","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drugs associated with behavioral addictions: Real world analysis using the WHO pharmacovigilance database","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2025.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique.","name":"copyright","label":"Copyright"}]}}